Description: Cyclerion Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of sGC pharmacology to discover, develop and commercialize breakthrough treatments for serious and orphan diseases. Cyclerion plans to advance its current portfolio of five differentiated sGC stimulator programs with distinct pharmacologic and biodistribution properties that are uniquely designed to target tissues of greatest relevance to the diseases they are intended to treat. These programs, each of which have important milestones in 2019, include olinciguat in Phase 2 development for sickle cell disease, praliciguat in Phase 2 trials for heart failure with preserved ejection fraction (HFpEF) and for diabetic nephropathy, IW-6463 in Phase 1 development for serious and orphan central nervous system diseases, and two late-stage discovery programs targeting serious liver and lung diseases, respectively.
Home Page: www.cyclerion.com
CYCN Technical Analysis
245 First Street
Cambridge,
MA
02142
United States
Phone:
857 327 8778
Officers
| Name | Title |
|---|---|
| Dr. Peter M. Hecht Ph.D. | CEO & Director |
| Ms. Cheryl Gault | Chief Operating Officer |
| Ms. Anjeza Gjino | CFO & Corp. Sec. |
| Dr. Todd Milne Ph.D. | Sr. VP of External Innovation |
| Ms. Jessica Rennekamp | Associate Director of Corp. Communications |
| Mr. Christopher Winrow Ph.D. | Sr. Director of Clinical Devel. & Neuroscience Program Lead |
| Ms. Jennifer Chickering Ph.D. | Sr. Director of Clinical Strategy |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.7109 |
| Price-to-Sales TTM: | 17.4285 |
| IPO Date: | 2019-04-02 |
| Fiscal Year End: | December |
| Full Time Employees: | 32 |